The prognostic effects of somatic mutations in ER-positive breast cancer

[1]  J. Olson,et al.  Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. , 2017, Cancer discovery.

[2]  M. Ellis,et al.  Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer , 2017, Clinical Cancer Research.

[3]  T. Graeber,et al.  Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. , 2017, Cancer discovery.

[4]  Ron Shamir,et al.  Extracting replicable associations across multiple studies: Empirical Bayes algorithms for controlling the false discovery rate , 2016, PLoS Comput. Biol..

[5]  Joshua F. McMichael,et al.  DoCM: a database of curated mutations in cancer , 2016, Nature Methods.

[6]  Christopher A. Miller,et al.  Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas. , 2016, Cell reports.

[7]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[8]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[9]  Zachary L. Skidmore,et al.  A genomic analysis of Philadelphia chromosome-negative AML arising in patients with CML , 2016, Blood Cancer Journal.

[10]  Obi L. Griffith,et al.  GenVisR: Genomic Visualizations in R , 2016, bioRxiv.

[11]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[12]  Obi L. Griffith,et al.  A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer , 2015, Clinical Cancer Research.

[13]  Obi L. Griffith,et al.  Genome Modeling System: A Knowledge Management Platform for Genomics , 2015, PLoS Comput. Biol..

[14]  V. Seshan,et al.  False Discovery Rates for Rare Variants From Sequenced Data , 2015, Genetic epidemiology.

[15]  Jinghui Zhang,et al.  Reply to Artifacts in the data of Hu et al. , 2015, Nature Genetics.

[16]  Nancy F. Hansen,et al.  Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1 , 2014, BMC Cancer.

[17]  S. Leung,et al.  Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration , 2014, Breast Cancer Research.

[18]  N. McGranahan,et al.  Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer. , 2014, Cancer research.

[19]  Rodrigo Dienstmann,et al.  Standardized decision support in next generation sequencing reports of somatic cancer variants , 2014, Molecular oncology.

[20]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[21]  Joshua F. McMichael,et al.  DGIdb - Mining the druggable genome , 2013, Nature Methods.

[22]  Li Ding,et al.  Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. , 2013, Cell reports.

[23]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[24]  Somasekar Seshagiri,et al.  Oncogenic ERBB3 mutations in human cancers. , 2013, Cancer cell.

[25]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[26]  M. Rieder,et al.  Erratum: Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants (Nature (2013) 493 (216-220) DOI: 10.1038/nature116) , 2013 .

[27]  Li Ding,et al.  Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.

[28]  William Pao,et al.  DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy , 2013, Clinical Cancer Research.

[29]  S. Gabriel,et al.  Analysis of 6,515 exomes reveals a recent origin of most human protein-coding variants , 2012, Nature.

[30]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[31]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[32]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[33]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[34]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[35]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[36]  E. Mardis,et al.  A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen , 2012, Clinical Cancer Research.

[37]  C. Swanton,et al.  Cancer chromosomal instability: therapeutic and diagnostic challenges , 2012, EMBO reports.

[38]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[39]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[40]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[41]  Jeroen F. J. Laros,et al.  LOVD v.2.0: the next generation in gene variant databases , 2011, Human mutation.

[42]  A. Ashworth,et al.  Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen , 2011, Proceedings of the National Academy of Sciences.

[43]  M. Tang,et al.  DDR1 triggers epithelial cell differentiation by promoting cell adhesion through stabilization of E-cadherin , 2011, Molecular biology of the cell.

[44]  Jonathan W. Pillow,et al.  POSTER PRESENTATION Open Access , 2013 .

[45]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[46]  Mark T. W. Ebbert,et al.  A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[47]  David P. Davis,et al.  Diverse somatic mutation patterns and pathway alterations in human cancers. , 2010, Nature.

[48]  D. Tu,et al.  A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[50]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[51]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[52]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[54]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[55]  S. Fröhling,et al.  High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. , 2007, Blood.

[56]  B. Efron.  Size, power and false discovery rates , 2007, 0710.2245.

[57]  K. Gelmon,et al.  Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  Charles M Perou,et al.  Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas , 2007, Breast Cancer Research.

[59]  M. Lavin,et al.  Deficiency in the catalytic subunit of DNA-dependent protein kinase causes down-regulation of ATM. , 2005, Cancer research.

[60]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[61]  Takeshi Corpora,et al.  Altered affinity of CBFβ-SMMHC for Runx1 explains its role in leukemogenesis , 2002, Nature Structural Biology.

[62]  Takeshi Corpora,et al.  Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis. , 2002, Nature structural biology.

[63]  T. Pawson,et al.  Discoidin Domain Receptor 1 Tyrosine Kinase Has an Essential Role in Mammary Gland Development , 2001, Molecular and Cellular Biology.

[64]  S. Fuqua,et al.  An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. , 1997, Cancer research.